Guangzhou KingMylab Pharmaceutical Research Co., Ltd (KingMylab) is one of China’s leading  providers of central laboratory and data services for clinical research. We are dedicated to delivering scientific, compliant, and one-stop comprehensive central laboratory solutions for clinical trials to our pharmaceutical and biotech partners both at home and abroad. KingMylab began in 2008 as the Clinical Trial Department of Guangzhou KingMed Diagnostics, China’s largest clinical diagnostics corporation, before becoming independent in 2020. One of the earliest labs of its kind in China. KingMylab to date has supported over 600 pharmaceutical companies around the globe across nearly 3,600 clinical trials from Phase I to Phase IV and helped secure approval for more than 60 new drugs.

KingMylab aims to offer the best clinical trial lab services for our clients across the world to aid in their quest to deliver innovative medicines to the patients who need them the most. With three state-of-the-art central laboratories located in Guangzhou, Shanghai, and Hong Kong, KingMylab provides a complete suite of experimental and analytical platforms to clients throughout China. In addition, we work in close collaboration with international lab partners to bring our services to local communities around the world. Through the fusion of digitalization with biotechnology, we continue to improve upon our clinical management, translation, and service capabilities. From our roots as a leading clinical laboratory to our growth today into a pioneering CRO, KingMylab is committed to providing one-stop clinical trial laboratory comprehensive solutions that cover the entirety of the drug research and development cycle, from preclinical discovery to clinical trial management to final market approval, by integrating our heritage of quality with our drive for innovation. This is reflected in our expanding international multi-center services that support  clinical research in a wide range of therapeutic areas, including but not limited to oncology, infectious, metabolic , inherited disorders, immunology, vaccines, and cell and gene therapy.

KingMylab strictly adheres to the highest quality industry standards, such as the GLP/GCP regulatory requirements of the NMPA, FDA, and EMA, and our central labs have all been accredited by both the CAP, CLIA, ISO15189 and ISO17025 building a seamless clinical trial laboratory service chain that covers translational medicine, biomarker discovery, bioanalysis, central laboratory testing and more, laying a foundation for a diverse portfolio of clinical trial CRO services.